Dashboard
1
Poor Management Efficiency with a low ROCE of 1.30%
- The company has been able to generate a Return on Capital Employed (avg) of 1.30% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of -5.33% and Operating profit at -210.90% over the last 5 years
3
Flat results in Mar 25
4
Risky -
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-21.79%
0%
-21.79%
6 Months
-15.06%
0%
-15.06%
1 Year
41.2%
0%
41.2%
2 Years
13.45%
0%
13.45%
3 Years
-11.0%
0%
-11.0%
4 Years
-30.83%
0%
-30.83%
5 Years
-43.01%
0%
-43.01%
ChemPartner PharmaTech Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-5.33%
EBIT Growth (5y)
-210.90%
EBIT to Interest (avg)
-10.12
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
0.60
Tax Ratio
0.24%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.30%
ROE (avg)
4.63%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.89
EV to EBIT
-26.67
EV to EBITDA
-67.77
EV to Capital Employed
5.58
EV to Sales
5.82
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-20.93%
ROE (Latest)
-15.74%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ
Mar'25
Dec'24
Change(%)
Net Sales
260.70
250.40
4.11%
Operating Profit (PBDIT) excl Other Income
-0.90
-125.50
99.28%
Interest
0.30
23.20
-98.71%
Exceptional Items
-0.00
-2.30
100.00%
Consolidate Net Profit
6.60
-164.70
104.01%
Operating Profit Margin (Excl OI)
-3.50%
-671.10%
66.76%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2025 is 4.11% vs -0.79% in Dec 2024
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2025 is 104.01% vs -13,825.00% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
964.80
1,132.70
-14.82%
Operating Profit (PBDIT) excl Other Income
77.80
124.50
-37.51%
Interest
26.90
32.30
-16.72%
Exceptional Items
-148.40
-863.00
82.80%
Consolidate Net Profit
-226.50
-916.90
75.30%
Operating Profit Margin (Excl OI)
-101.50%
-57.80%
-4.37%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -14.82% vs -14.13% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 75.30% vs -342.31% in Dec 2023
About ChemPartner PharmaTech Co., Ltd. 
ChemPartner PharmaTech Co., Ltd.
Miscellaneous
No Details Available.
Company Coordinates 
No Company Details Available






